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SUPPLEMENT ARTICLE
Acceptability and Satisfaction Associated With the
Introduction of the PrePex Circumcision Device in
Maputo, Mozambique
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Background: Adult device circumcision may potentially reach
more men in Sub-Saharan Africa, with fewer human resource and
capacity needs than surgical procedures. Despite these advantages,
little is known about device acceptability, including pain and
maintaining the device in situ.
Methods: Healthy, HIV-negative men, between 18 and 49 years, in
a Maputo clinic, were consecutively asked to participate in
a circumcision device study that included assessing acceptability.
Clinical forms and self-administered surveys were used to collect
data at various times during the circumcision process for consenting
men. Data were entered into a central database and analyzed using
statistical software.
Results: Between May and July, 2013, 504 men received device
circumcision. Placement was painless for 98.2% of the male
population, but the pain was more common during removal with
38.3% reporting severe or unbearable and 21.5% moderate pain.
Satisfaction was high at both time points with 88.8% and 92.6% of
men being very or somewhat satisfied at placement and removal,
respectively. Half of the male population (50.2%) was very or
somewhat comfortable with the device in situ; whereas, 36.8% were
somewhat or very uncomfortable. Common device difficulties
experienced were painful erections (38.5%) and difficult urination
(21.8%) and hygiene (21.4%). By the final clinic visit at day 49,
90.4% of them were very or somewhat satisfied with the procedure.
Discussion: High levels of satisfaction were reported for device
circumcision, despite the pain noted during removal and some
challenges with the device in situ. Given the advantages and
acceptability among Mozambican men in this study, device
circumcision could be offered, when clinically appropriate, as an
alternative to surgery.
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INTRODUCTION
Male circumcision (MC) has been practiced by many
communities in Mozambique for centuries, and, in addition to
religious significance, circumcision is often served as a rite of
passage to adulthood and was performed during adolescent
initiation schools.1,2 Approximately 51% of the Mozambican
male population, aged 15–49 years, are circumcised; how-
ever, there is significant variation across the nation’s 11
provinces. HIV prevalence is consistently lower in the
provinces where MC is commonly practiced and higher
where fewer men are circumcised.3
MC services for HIV prevention were initiated in
Mozambique in November 2009 with the Ministry of Health
(MOH) setting a goal of circumcising 2 million male persons
between the ages of 10 and 49 years by the end of 2017.4
More than 440,000 male persons have been circumcised
through December 2014,5 however, progress on scaling up
the intervention has been slower than expected, and expan-
sion has been hampered by challenges related to human
resources and infrastructure. Recent technological advances,
such as circumcision devices, provide viable options for
addressing some of the operational challenges faced by
resource-limited countries like Mozambique, while possibly
reaching more of the male population with MC services.6
Circumcision devices are widely used for infants with
great success, but experience with adolescents and adults has
been limited, particularly in Sub-Saharan Africa, where rapid
expansion of MC programs for HIV prevention is most urgent.
One nonsurgical option for adult MC is PrePex, an elastic
collar compression device. Although various studies have
determined the safety of devices like PrePex,7,8 there is less
information about device circumcision acceptability among
men, which may vary by a number of factors including
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sociodemographics.9 This article describes a PrePex study that
was conducted, in part, to assess the acceptability of the device
and procedure in Mozambique. We sought to document
attitudes towards and experiences with device circumcision
(eg, acceptability during the procedure and during the healing
period with the device in situ), effects on daily activities, pain,
and satisfaction with final cosmetic results. These data will
assist the MOH with recommendations on the use of the device
in adult MC programs, including demand creation messages
and comprehensive counseling and informational materials.
METHODS
Study Design and Procedures
Our prospective cohort study recruited healthy, HIV-
negative men, between the ages of 18 and 49, who were
accessing standard surgical circumcision services at the Jose
Macamo Health Center in Maputo, Mozambique. Men
seeking MC were consecutively asked about their interest in
PrePex device circumcision and participation in the study
after receiving detailed information about this alternative
method. Potential participants received a medical history
screening and a genital examination conducted by the PrePex
providers, to determine that they were in overall good
physical health. Potential participants also were required to
consent for HIV counseling and testing. Serological testing
for HIV was conducted using the Mozambique MOH national
algorithm with Determine HIV-1/2 and Uni-Gold HIV rapid
test kits. Men with contraindications for device circumcision
(eg, genital or penile conditions such as physical abnormal-
ities, active infections, prepuces with limited flexibility
bleeding disorders, and diabetes) or who were HIV-positive
were not permitted to participate and were referred for
standard surgical circumcision, if appropriate.
Enrollment was limited to potential participants who
were capable of providing informed consent, understood and
agreed to the study procedures and requirements (eg, abstain-
ing from sexual intercourse and masturbation for 6 weeks after
removal, returning to the health care facility for follow-up
visits, permitting photographs of the circumcision process, and
agreeing to complete surveys and interviews), lived within 25
km of the facility, provided valid contact information (ie,
a working telephone number, address of residence, and place of
employment), were able to communicate in Portuguese, and
had a penis that fit into one of the 5 PrePex ring sizes.
Eligible men received PrePex counseling before device
placement. PrePex procedures were performed at the Jose
Macamo Health Center by 4 nurses. The nurses were trained
and certified to perform PrePex circumcisions for this study by
PrePex Master Trainers and certified PrePex doctors in
Mozambique. The PrePex device was removed on day 7 at
the health center and the men returned for clinical follow-up on
days 28 and 49. We sought to enroll and circumcise 500 men.
Study Measures and Instruments
Providers completed detailed case report forms (CRFs)
to collect data on all clinical processes, outcomes, and adverse
events on days 0 (placement) and 7 (removal), and to assess
wound healing during the 2 follow-up clinic visits that were
28 and 49 days after device placement. The study team also
conducted follow-up telephone calls on days 2, 14, and 21
after placement to assess pain, discomfort, healing, and
adherence to medical instructions, including sexual absti-
nence. Pain was measured using a visual analog scale (VAS)
with 6 levels (0, 2, 4, 6, 8, and 10) from least to most painful
and was assessed during placement, while the device was in
situ, during removal, and after removal. The clinical data were
supplemented by a self-administered survey that all men
completed at 5 time points: before placement, immediately
after placement, 7 days after placement (after device
removal), 28 days after placement, and 49 days after
placement. Clinical outcomes are presented elsewhere in this
journal edition (see “Safety and Efficacy of the PrePex Male
Circumcision Device: Results from Pilot Implementation
studies in Mozambique, South Africa and Zambia”).
Data Management and Analysis
Data on the circumcision procedure collected during
clinic visits and telephone calls were recorded by hand on the
study CRFs. Once verified by the study’s clinical supervisor,
data from the CRFs were digitally entered using CSPro
software version 3.3 (Washington, DC) and analyzed using
SPSS (Armonk, NY). Paper surveys were completed by
clients, and these data were entered and processed in SPSS.
All data were double entered to ensure accuracy.
Ethical Considerations
Participants provided written informed consent before
participating in study activities. Reimbursement for participa-
tion was offered as compensation for the time required to
complete surveys and transportation costs to return to the clinic
for follow-up visits. The total value of the reimbursement was
estimated at approximately US $25. The study protocol was
approved by the National Bioethics Committee for Health
(Comité Nacional de Bioética para a Saúde) of Mozambique,
Johns Hopkins University, and the Center for Global Health in
the US Centers for Disease Control and Prevention.
RESULTS
A total of 608 men were evaluated to participate in this
study and 104 of them were determined to be ineligible.
Reasons for ineligibility included HIV infection (n = 65,
62.5%), other medical conditions (eg, phimosis) (n = 16,
15.4%), and inability to adhere to study procedures (eg, no
cell phone) (n = 23, 22.1%). A sample of 504 men received
PrePex circumcision between May and July, 2013. Approx-
imately 70% of the men circumcised using the PrePex device
were 24 years of age or younger and not married. Most men
(58.7%) were employed at the time of circumcision and
35.7% were students. Men selecting device circumcision were
well educated with 84.1% attaining a secondary or post-
secondary education. The demographic characteristics of the
study sample are included in Table 1.
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Details on pain and overall satisfaction throughout the
PrePex circumcision process and required clinical follow-up
are presented in Table 2. Pain on day 0 was assessed at 3
sequential time points: during placement (presented in the
table) and 15 and 60 minutes after placement. The actual
placement was painless for almost all men (98.2%). Perceived
pain was minimal for men at 15 (n = 503) and 60 (n =
48) minutes after placement at 99.2% and 97.9%, respec-
tively. Pain was also measured at 3 points on day 7, including
before, during (presented in the table) and after removal.
Before device removal, 91.0% of men reported no or slight
pain (VAS 0 and 2), and 2.6% experienced severe or
unbearable pain (VAS 8 and 10). Pain levels increased
notably during removal with 38.3% of men reporting severe
or unbearable pain (VAS 8 and 10), and 21.5% of men
reporting moderate pain (VAS 6); however, the reported pain
lessened within minutes. After removal, the level of pain
decreased, with 54.1% of men reporting no or slight pain;
however, 14% remained with severe or unbearable pain. The
level of pain on days 28 and 49 remained very low, with
96.3% and 98.5% of men, respectively, reporting no pain.
Related to satisfaction, 88.8% of men reported being very
or somewhat satisfied with the placement (day 0), and 92.6%
reported similar levels of satisfaction with the removal
procedure (day 7). Satisfaction remained high on days 28 and
49, with 91.4% and 90.4% of men reporting to be very or
somewhat satisfied, respectively. Only 4.5% of men on day 28
and 1.8% on day 49 were somewhat or very dissatisfied with
the overall circumcision process. By study completion, more
than 80% had talked had about PrePex. Of these men,
approximately half (49.5%) talked about PrePex with friends,
followed by female partners (36.9%), family members (7.8%),
and work colleagues (2.7%). Additionally, by day 49, approx-
imately 90% of men had or intended to recommend PrePex.
Table 3 presents data collected after removal on day 7
that summarizes experiences with the PrePex device in situ.
Among all men, half (50.2%) were very or somewhat
comfortable wearing the device and similar comfort levels
were reported regardless of age. In contrast, 36.8% of all men
said that they were very or somewhat uncomfortable with the
device in situ, ranging from 34.5% among 20- to 24-year-old
to 41.5% of 18- to 19-year old men. Study providers
instructed the participating men to gently clean their penis
twice per day using warm water and mild soap. Following
these instructions was very or somewhat easy for 63.6% of all
men, but 22.6% of them said that maintaining their hygiene
was a little difficult. Most men found that performing routine
activities (eg, dressing) and working or attending school was
very or somewhat easy, 59.7% and 67%, respectively.
PrePex-related absence from work or school was limited to
1 day or less for 60.4% of the employed men and students.
Older men were less likely to take time off because of the
procedure (P = 0.025). The most common difficulty experi-
enced during the 7 days was painful or uncomfortable
erections, which was reported by 38.5% of all men.
Additionally, almost equal proportions of men indicated that
they had difficulties urinating because of meatal narrowing
(21.8%) and cleaning their genitals (21.4%); 29.9% of all men
reported that they did not experience any difficulties. There
were statistically significant differences by age for urination
difficulties (P = 0.037) and for men who did not report
difficulties (P = 0.011). Few men (3.5%) said that they had
sexual intercourse or masturbated while wearing the device.
A multiple logistic regression model measuring the
relationship between PrePex satisfaction after complete heal-
ing at day 49 found that satisfaction was neither influenced by
specific demographic variables (eg, age, student and employ-
ment status, educational attainment, or marital status) nor the
pain level at device removal.
DISCUSSION
Our study documented a high level of satisfaction with
PrePex device circumcision and the associated processes
among Mozambican men in Maputo. At placement, 70.8% of
men were very satisfied and 18% were somewhat satisfied; of
note, this increased slightly to 74.4% and 18.2% of men,
respectively, at removal. Although the proportion that
reported being very satisfied had diminished by day 28, by
day 49 the proportion increased to a high of 82.0%. We
believe that the moderate improvement in the reported
satisfaction levels observed on day 7 was related to the relief
of device removal; similarly, the level of satisfaction on the
TABLE 1. Sociodemographic Characteristics of Men













Single/not married 343 (68.0)
Married 62 (12.3)




Primary school 77 (15.3)
Secondary school 258 (51.2)
Any postsecondary schooling 166 (32.9)
Does not know/refused 1 (0.2)
Missing 2 (0.4)
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last day of follow-up is likely because healing was either
complete or nearly complete. We further considered this final
satisfaction measure to be an indication of a high degree of
contentment with the final circumcision outcome. We
explored the acceptability of pain and having the device in
situ for 7 days, which we hypothesized would have the most
impact on procedure acceptance among the general male
population. Published literature from Rwanda and Kenya has
shown that men experience some pain at specific points
throughout the device circumcision process, most notably at
night with erections and when the device is removed.6,7,10
This was also evident in our data. More than 90% of men said
that they did not experience pain, and there were no clients
that had a lot or unbearable pain at placement. During the
device removal, the reported pain intensified, but lessened
within minutes and was insignificant for almost all men
during the 2 clinical follow-up visits at days 28 and 49.
Association between satisfaction and pain was neither
observed in our logistic regression nor by the key demo-
graphic variables. This finding was unexpected. We hypoth-
esized that students and employed men would be highly
satisfied with PrePex because of the fact that, in theory, less
time off is required and that men who experienced less pain at
removal would experience greater satisfaction. Conversely,






Follow-Up Visit Day 28
(N = 490)
Follow-Up Visit Day 49
(N = 478)
n (%) n (%) n (%) n (%)
Satisfaction with the PrePex device Placement Removal Overall process Overall process
Very satisfied 357 (70.8) 373 (74.4) 342 (69.8) 392 (82.0)
Somewhat satisfied 91 (18.0) 91 (18.2) 106 (21.6) 40 (8.4)
Neither satisfied nor dissatisfied 24 (4.8) 15 (3.0) 12 (2.5) 12 (2.5)
Somewhat dissatisfied 5 (1.0) 8 (1.6) 15 (3.1) 4 (0.8)
Very dissatisfied 1 (0.2) 5 (1.0) 7 (1.4) 5 (1.0)
Does not know 11 (2.2) 3 (0.6) 6 (1.2) 2 (0.4)
Refused to answer/missing 15 (3.0) 6 (1.2) 2 (0.4) 23 (4.8)
Level of pain During placement During removal
No pain/VAS 0 495 (98.2) 13 (2.6) 472 (96.3) 471 (98.5)
Slight pain/VAS 2 6 (1.2) 71 (14.2) 15 (3.1) 3 (0.6)
Mild pain/VAS 4 1 (0.2) 115 (23.0) 2 (0.4) 0 (0)
Moderate pain/VAS 6 2 (0.4) 108 (21.5) 0 (0) 3 (0.6)
Severe pain/VAS 8 0 (0) 128 (25.5) 0 (0) 0 (0)
Unbearable pain/VAS 10 0 (0) 64 (12.8) 0 (0) 0 (0)
Refused to answer/missing 0 (0) 2 (0.4) 1 (0.2) 1 (0.2)
Talked with others about PrePex circumcision
Yes — 408 (81.4) 428 (87.3) 404 (84.5)
No — 37 (7.4) 38 (7.8) 31 (6.5)
Refused to answer/missing — 56 (11.2) 24 (4.9) 43 (9.0)
Recommended PrePex circumcision to friends or
relatives
Yes — — 436 (89.0) 418 (87.4)
No — — 19 (3.9) 34 (7.1)
Refused to answer/missing — — 35 (7.1) 26 (5.4)
Will recommend PrePex circumcision to friends and
relatives
Yes — — 409 (83.5) 435 (91.0)
No — — 55 (11.2) 15 (3.1)
Does not know/refused to answer — — 26 (5.3) 28 (5.9)
No. persons who will recommend to have PrePex
circumcision
0 — — — 34 (7.1)
1–2 — — — 108 (22.6)
3–5 — — — 127 (26.6)
6–10 — — — 39 (8.2)
11 or more — — — 121 (25.3)
Does not know — — — 24 (5.0)
Refused to answer/missing — — — 25 (5.2)
*One client experienced a device dislocation and 2 clients removed their devices and were excluded from follow-up on day 7 and the remaining study visits.
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Men (N = 501)
PrePex Circumcised Men,
Ages 18–19 (N = 154)
PrePex Circumcised Men,
Ages 20–24 (N = 197)
PrePex Circumcised Men,
Ages ‡25 (N = 150) P, x2
Testn (%) n (%) n (%) n (%)
Comfort with the PrePex device
in place
0.768
Very comfortable 76 (15.2) 21 (13.6) 30 (15.2) 25 (16.7)
Somewhat comfortable 175 (35.0) 51 (33.1) 70 (35.5) 54 (36.0)
Neither comfortable nor
uncomfortable
41 (8.2) 12 (7.8) 17 (8.6) 12 (8.0)
Somewhat uncomfortable 137 (27.3) 49 (31.8) 45 (22.8) 43 (28.7)
Very uncomfortable 48 (9.5) 15 (9.7) 23 (11.7) 10 (6.7)
Does not know 9 (1.8) 2 (1.3) 5 (2.5) 2 (1.3)
Refused to answer/missing 15 (3.0) 4 (2.6) 7 (3.6) 4 (2.7)
Ability to maintain hygiene
with the PrePex device in
place
0.340
Very easy 137 (27.3) 37 (24.0) 54 (27.4) 46 (30.7)
Somewhat easy 182 (36.3) 59 (38.3) 67 (34.0) 56 (37.3)
Neither easy nor difficult 51 (10.2) 23 (14.9) 14 (7.1) 14 (9.3)
Somewhat difficult 95 (19.0) 28 (18.2) 46 (23.4) 21 (14.0)
Very difficult 18 (3.6) 5 (3.2) 6 (3.0) 7 (4.7)
Does not know 4 (0.8) 1 (0.6) 2 (1.0) 1 (0.7)
Refused to answer/missing 14 (2.8) 1 (0.6) 8 (4.1) 5 (3.3)
Ability to perform routine
activities with the PrePex
device in place
0.248
Very easy 114 (22.8) 31 (20.1) 37 (18.8) 46 (30.7)
Somewhat easy 185 (36.9) 57 (37.0) 77 (39.1) 51 (34.0)
Neither easy nor difficult 62 (12.4) 24 (15.6) 22 (11.2) 16 (10.7)
Somewhat difficult 103 (20.5) 33 (21.4) 46 (23.4) 24 (16.0)
Very difficult 18 (3.6) 6 (3.9) 7 (3.6) 5 (3.3)
Does not know 7 (1.4) 3 (1.9) 1 (0.5) 3 (2.0)
Refused to answer/missing 12 (2.40) 0 (0) 0 (3.6) 5 (3.3)
Ability to work or attend school
with the PrePex device in
place
0.143
Very easy 130 (30.9) 41 (28.7) 39 (25.5) 50 (40)
Somewhat easy 152 (36.1) 51 (35.6) 59 (38.6) 42 (33.6)
Neither easy nor difficult 33 (7.8) 14 (9.8) 12 (7.8) 7 (5.6)
Somewhat difficult 88 (20.9) 28 (19.6) 36 (23.5) 24 (19.2)
Very difficult 14 (3.3) 6 (4.2) 7 (4.6) 1 (0.8)
Does not know 4 (1.0) 3 (2.1) 0 (0.0) 1 (0.8)
No. days of work or school lost
as a result of PrePex
circumcision
0.025
Less than 1 209 (60.4) 55 (54.5) 75 (56.0) 79 (71.2)
1–2 52 (15.0) 13 (12.8) 24 (17.9) 15 (13.5)
3–4 19 (5.5) 4 (4.0) 10 (7.5) 5 (4.5)
5–6 10 (2.9) 2 (2.0) 5 (3.7) 3 (2.7)
7 45 (13.0) 22 (21.7) 14 (10.4) 9 (8.1)
Does not know 11 (3.2) 5 (5.0) 6 (4.5) 0 (0.0)
Had sex or masturbated with
the PrePex device in place
0.766
Yes 17 (3.4) 5 (3.2) 8 (4.1) 4 (2.7)
No 470 (93.8) 148 (96.1) 180 (91.4) 140 (93.3)
Refused to answer/missing 14 (2.8) 1 (0.6) 9 (4.6) 6 (4.0)
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we initially believed that married men would potentially have
less satisfaction because of the slightly longer, necessary
abstinence period. We found that maintaining the device in
situ for 7 days did not pose a challenge for most men in our
study, who reported that they were able to urinate, clean their
genitals, and abstain from sex and masturbation. In fact, in
older men greater than 25 years of age, who would be the
likely priority for demand creation of device circumcision,
relatively few difficulties were reported.
More than 8 in 10 device circumcised men talked with
others about PrePex. By day 49, 87.4% of men had already
recommended PrePex, and 91.0% of them said that they would
recommend it in the future. Experiences in Mozambique, where
demand creation for voluntary medical male circumcision was
initially restricted, have shown that interpersonal communica-
tion is one of the most important factors for encouraging men to
access services. This has also been validated by other research
and documented in other settings,11,12 and likely will be critical
for the device’s successful introduction as a tool for voluntary
medical male circumcision scale-up.
Several implementation and programmatic factors
posed limitations to this study. The study was conducted at
1 site in a periurban area of the capital, Maputo. As a result,
acceptability in more rural areas and other regions of the
country remains unknown. Because the MOH considers
expansion to ensure that there are no cultural or social
barriers to the acceptance of device circumcision, similar
rapid field studies in other Mozambican locations will be
necessary. Our study population was fairly young with similar
demographics, therefore it is difficult to know how 25-year-
old and older men will respond to device circumcision.
However, the small number of older men circumcised through
this study found it to be an acceptable procedure and these
men were some of the most satisfied and comfortable people
with the device. Another study-related limitation is that we
collected very minimal information from men who refused or
were ineligible for device circumcision as a basis for
comparison. However, it is noteworthy that our study
successfully recruited for PrePex predominantly among men
seeking surgical circumcision who had no previous informa-
tion about devices. Other limitations related to study imple-
mentation included the lack of validation of the pain scale
before the start of the study; lower follow-up rates for
telephone calls on days 2 (85.9%), 14 (80%), and 21
(88.2%) in comparison to clinic visit follow-ups, which
ranged from 95.4% to 100%; and varying completeness of
the self-administered surveys that were answered after long
clinic visits. It is difficult to ascertain and quantify the degree
to which these issues may have biased the data. Reported pain
levels were consistent with those found in other studies.8,10
Although lower than desired, the telephone response rate was
better than participation rates for epidemiologic studies
conducted in the United States, including the Behavioral
Risk Factor Surveillance Survey,13 and there were no key
differences among men noted in incomplete questionnaire
responses. Furthermore, during routine program services that
include device circumcision, study-related issues (eg, survey
completeness and follow-up retention) will not be relevant.
Despite these limitations, we believe that the inclusion of
device circumcision as part of the national program would be
well accepted by Mozambican men. Similar acceptance of
PrePex has been observed in Rwanda, where the device has
been the primary method of circumcision for national HIV
prevention efforts, and in Kenya, where the high acceptability
of PrePex circumcision was reported despite some client
concerns about odor and pain during removal.8,14 Our study
provides enhanced understanding of the satisfaction associated
with the device and its procedures, which will assist with
developing communication materials to support this circumci-
sion method. Specifically, information is needed that empha-
sizes practical strategies for maintaining hygiene and fostering
realistic expectations about potential difficulties, including pain




Men (N = 501)
PrePex Circumcised Men,
Ages 18–19 (N = 154)
PrePex Circumcised Men,
Ages 20–24 (N = 197)
PrePex Circumcised Men,
Ages ‡25 (N = 150) P, x2
Testn (%) n (%) n (%) n (%)
Difficulties experienced with
the PrePex device in place‡
Painful or bothersome
erections
193 (38.5) 59 (38.3) 81 (41.1) 53 (35.3) 0.547
No difficulties experienced 150 (29.9) 54 (35.1) 44 (22.3) 52 (34.7) 0.011
Difficult to urinate 109 (21.8) 38 (24.7) 50 (25.4) 21 (14.0) 0.037
Difficult to keep the penis
and foreskin clean
107 (21.4) 34 (22.1) 49 (24.9) 24 (16.0) 0.161
Difficult to keep the PrePex
device in place
35 (7.0) 12 (7.8) 13 (6.6) 10 (6.7) 0.955
Difficult to abstain from sex
or masturbation
31 (6.2) 10 (6.5) 16 (8.1) 5 (3.3) 0.199
Difficult to hide the PrePex
device under clothing
38 (7.6) 18 (11.7) 12 (6.1) 8 (5.3) 0.107
*Clients completed this survey on day 7 after device removal and clinical observations.
‡Multiple responses were permitted.
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at removal and with erections. Demand creation should
capitalize on the enthusiasm for device circumcision observed
among men in our sample and use their willingness to talk
about and recommend PrePex to mobilize other men. Addi-
tionally, our study underscores the need for exploration of pain
management techniques to assist men with the discomfort
experienced at various points in the circumcision process.
Finally, the ongoing monitoring of factors associated with
PrePex acceptability is warranted as active surveillance begins
in many countries and we recommend incorporating qualitative
methodologies to explore aspects of the process that are
acceptable/satisfactory and unacceptable/unsatisfactory.
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